Project in which Diamyd Medical is participating partner receives financing from VINNOVA
Diamyd Medical today announced that Linköping University with Professor Johnny Ludvigsson, as project leader, will receive approximately SEK 0.5 million from VINNOVA, the Swedish innovation agency, to build a network of pediatric clinics to facilitate the conduct of clinical trials in type 1 diabetes. Diamyd Medical and Novo Nordisk, as well as pediatric clinics in Linköping, Norrköping, Jönköping, Stockholm, Uddevalla, Lund and Malmö are participating partners in the project.
“A prerequisite for progress in research on diabetes in children and adolescents is more clinical studies”, says Johnny Ludvigsson, Professor at Linköping University and Principal Investigator of sevaral clinical trials with the diabetes vaccine Diamyd®. “Using the new financing of our network, we hope to be able to both increase the number of clinical trials in type 1 diabetes and facilitate the conduct of them. The VINNOVA grant is really welcomed and encouraging. I see opportunities for Sweden to be able to get a distinct and leading role in this area.”
About Diamyd Medical
Diamyd Medical is dedicated to finding a cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cell and medical technology.
Diamyd Medical develops the diabetes vaccine Diamyd®, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. Six clinical studies are ongoing with Diamyd®. GABA constitutes alongside with the diabetes vaccine a key asset in Diamyd Medical and the Company uses its GABA in-licensed technology to develop a proprietary GABA drug product. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB (former Cellaviva AB). Diamyd Medical also has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA.
Diamyd Medical’s B-share is traded on Nasdaq Stockholm First North under the ticker DMYD B. Remium Nordic AB is the Company’s Certified Adviser.
For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com
Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com Reg. no.: 556242-3797 Website: www.diamyd.com
This information is information that Diamyd Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on November 23, 2016.